{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:12:37Z","timestamp":1784157157937,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11916-025-01437-5","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T12:39:37Z","timestamp":1765802377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Ketamine Infusion for Treatment of Opioid Use Disorder in Patients with Chronic Pain: a Narrative Review"],"prefix":"10.1007","volume":"30","author":[{"given":"Alan D.","family":"Kaye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison C.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah I.","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Potharaju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"13","key":"1437_CR1","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","volume":"284","author":"AT McLellan","year":"2000","unstructured":"McLellan AT, Lewis DC, O\u2019Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689\u201395. https:\/\/doi.org\/10.1001\/jama.284.13.1689.","journal-title":"JAMA"},{"issue":"1","key":"1437_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","volume":"26","author":"ND Volkow","year":"2021","unstructured":"Volkow ND, Blanco C. The changing opioid crisis: development, challenges and opportunities. Mol Psychiatry. 2021;26(1):218\u201333. https:\/\/doi.org\/10.1038\/s41380-020-0661-4.","journal-title":"Mol Psychiatry"},{"key":"1437_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fpsyt.2018.00277","volume":"9","author":"JL Jones","year":"2018","unstructured":"Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE. Efficacy of ketamine in the treatment of substance use disorders: a systematic review. Front Psychiatry. 2018;9:277. https:\/\/doi.org\/10.3389\/fpsyt.2018.00277.","journal-title":"Front Psychiatry"},{"issue":"1","key":"1437_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1112-2","volume":"16","author":"L Lalanne","year":"2016","unstructured":"Lalanne L, Nicot C, Lang J-P, Bertschy G, Salvat E. Experience of the use of Ketamine to manage opioid withdrawal in an addicted woman: a case report. BMC Psychiatry. 2016;16(1):395. https:\/\/doi.org\/10.1186\/s12888-016-1112-2.","journal-title":"BMC Psychiatry"},{"key":"1437_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","volume":"142","author":"I. Ivan Ezquerra-Romano","year":"2018","unstructured":"Ezquerra-Romano I. Ivan, Lawn W, Krupitsky E, Morgan CJA. Ketamine for the treatment of addiction: evidence and potential mechanisms. Neuropharmacology. 2018;142:72\u201382. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.017.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1437_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.bcp.2007.06.039","volume":"75","author":"JT Gass","year":"2008","unstructured":"Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol. 2008;75(1):218\u201365. https:\/\/doi.org\/10.1016\/j.bcp.2007.06.039.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"1437_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1124\/pr.111.005108","volume":"64","author":"AE Autry","year":"2012","unstructured":"Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012;64(2):238\u201358. https:\/\/doi.org\/10.1124\/pr.111.005108.","journal-title":"Pharmacol Rev"},{"key":"1437_CR8","doi-asserted-by":"publisher","first-page":"1552084","DOI":"10.3389\/fpsyt.2025.1552084","volume":"16","author":"MR Shen","year":"2025","unstructured":"Shen MR, et al. Ketamine in treating opioid use disorder and opioid withdrawal: a scoping review. Front Psychiatry. 2025;16:1552084. https:\/\/doi.org\/10.3389\/fpsyt.2025.1552084.","journal-title":"Front Psychiatry"},{"key":"1437_CR9","doi-asserted-by":"publisher","first-page":"209705","DOI":"10.1016\/j.josat.2025.209705","volume":"175","author":"R Janssen-Aguilar","year":"2025","unstructured":"Janssen-Aguilar R, et al. Role of ketamine in the treatment of substance use disorders: A systematic review. J Subst Use Addict Treat. 2025;175:209705. https:\/\/doi.org\/10.1016\/j.josat.2025.209705.","journal-title":"J Subst Use Addict Treat"},{"issue":"1","key":"1437_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","volume":"107","author":"CJA Morgan","year":"2012","unstructured":"Morgan CJA, Curran HV, Independent Scientific Committee on Drugs. Ketamine use: a review. Addiction. 2012;107(1):27\u201338. https:\/\/doi.org\/10.1111\/j.1360-0443.2011.03576.x.","journal-title":"Addiction"},{"key":"1437_CR11","doi-asserted-by":"crossref","unstructured":"Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol. Psychiatry. 2018; 27.","DOI":"10.1016\/S0924-977X(17)30999-9"},{"issue":"44","key":"1437_CR12","doi-asserted-by":"publisher","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","volume":"36","author":"CF Zorumski","year":"2016","unstructured":"Zorumski CF, Izumi Y, Mennerick S. Ketamine: NMDA receptors and beyond. J Neurosci. 2016;36(44):11158\u201364. https:\/\/doi.org\/10.1523\/JNEUROSCI.1547-16.2016.","journal-title":"J Neurosci"},{"key":"1437_CR13","doi-asserted-by":"publisher","unstructured":"Weckmann K et al. Ketamine\u2019s effects on the glutamatergic and gabaergic systems: a proteomics and metabolomics study in mice.\u00a0Mol Neuropsychiatry. 2019;5(1): 1. https:\/\/doi.org\/10.1159\/000493425.","DOI":"10.1159\/000493425"},{"issue":"2","key":"1437_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/0269881120959644","volume":"35","author":"LA Jelen","year":"2021","unstructured":"Jelen LA, Young AH, Stone JM. Ketamine: a tale of two enantiomers. J Psychopharmacol. 2021;35(2):109\u201323. https:\/\/doi.org\/10.1177\/0269881120959644.","journal-title":"J Psychopharmacol"},{"key":"1437_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.107998","volume":"168","author":"C Wilson","year":"2020","unstructured":"Wilson C, Li S, Hannan AJ, Renoir T. Antidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction. Neuropharmacology. 2020;168:107998. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.107998.","journal-title":"Neuropharmacology"},{"key":"1437_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pharmthera.2019.02.017","volume":"199","author":"TH Pham","year":"2019","unstructured":"Pham TH, Gardier AM. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. Pharmacol Ther. 2019;199:58\u201390. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.02.017.","journal-title":"Pharmacol Ther"},{"issue":"7","key":"1437_CR17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.bpsc.2020.06.015","volume":"6","author":"MM Vasavada","year":"2021","unstructured":"Vasavada MM, et al. Effects of serial ketamine infusions on corticolimbic functional connectivity in major depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6(7):735\u201344. https:\/\/doi.org\/10.1016\/j.bpsc.2020.06.015.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"1437_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2021.105091","volume":"72","author":"S Liu","year":"2021","unstructured":"Liu S, Tao G, Zhou C, Wang Q, Wang W, Fei X. Ketamine inhibits neuronal differentiation by regulating brain-derived neurotrophic factor (BDNF) signaling. Toxicol In Vitro. 2021;72:105091. https:\/\/doi.org\/10.1016\/j.tiv.2021.105091.","journal-title":"Toxicol In Vitro"},{"issue":"2","key":"1437_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/bcp.12094","volume":"77","author":"M Niesters","year":"2014","unstructured":"Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014;77(2):357\u201367. https:\/\/doi.org\/10.1111\/bcp.12094.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1437_CR20","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/aps.2016.5","volume":"37","author":"M Gao","year":"2016","unstructured":"Gao M, Rejaei D, Liu H. Ketamine use in current clinical practice. Acta Pharmacol Sin. 2016;37(7):865\u201372. https:\/\/doi.org\/10.1038\/aps.2016.5.","journal-title":"Acta Pharmacol Sin"},{"key":"1437_CR21","unstructured":"Orhurhu VJ, Roberts JS, Ly N, Cohen SP. Ketamine in acute and chronic pain management, in StatPearls, treasure island (FL). StatPearls Publishing. 2025. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539824\/. Accessed 16 June 16 2025. [Online]."},{"key":"1437_CR22","doi-asserted-by":"publisher","unstructured":"Schwenk ES, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American society of regional anesthesia and pain medicine, the American academy of pain medicine, and the American society of anesthesiologists. Reg Anesth Pain Med. 2018;1. https:\/\/doi.org\/10.1097\/AAP.0000000000000806.","DOI":"10.1097\/AAP.0000000000000806"},{"issue":"11","key":"1437_CR23","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1097\/EJA.0000000000001588","volume":"38","author":"L Carrara","year":"2021","unstructured":"Carrara L, et al. The impact of bolus versus continuous infusion of intravenous ketamine on bispectral index variations and desflurane administration during major surgery: the KETABIS study. Eur J Anaesthesiol. 2021;38(11):1168\u201379. https:\/\/doi.org\/10.1097\/EJA.0000000000001588.","journal-title":"Eur J Anaesthesiol"},{"issue":"4","key":"1437_CR24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/00000542-198310000-00005","volume":"59","author":"PF White","year":"1983","unstructured":"White PF. Use of continuous infusion versus intermittent bolus administration of fentanyl or ketamine during outpatient anesthesia. Anesthesiology. 1983;59(4):294\u2013300. https:\/\/doi.org\/10.1097\/00000542-198310000-00005.","journal-title":"Anesthesiology"},{"issue":"5","key":"1437_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/ACO.0000000000000916","volume":"33","author":"W Barrett","year":"2020","unstructured":"Barrett W, Buxhoeveden M, Dhillon S. Ketamine: a versatile tool for anesthesia and analgesia. Curr Opin Anaesthesiol. 2020;33(5):633\u20138. https:\/\/doi.org\/10.1097\/ACO.0000000000000916.","journal-title":"Curr Opin Anaesthesiol"},{"issue":"3","key":"1437_CR26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14228","volume":"13","author":"K Goddard","year":"2021","unstructured":"Goddard K, Sampson C, Bedy S-M, Ghadban R, Stilley J. Effect of ketamine on cardiovascular function during procedural sedation of adults. Cureus. 2021;13(3):3. https:\/\/doi.org\/10.7759\/cureus.14228.","journal-title":"Cureus"},{"issue":"5","key":"1437_CR27","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1097\/MS9.0000000000003232","volume":"87","author":"R Sayad","year":"2025","unstructured":"Sayad R, et al. Safety considerations and risk mitigation strategies for ketamine use: a comprehensive review. Ann Med Surg. 2025;87(5):2829\u201337. https:\/\/doi.org\/10.1097\/MS9.0000000000003232.","journal-title":"Ann Med Surg"},{"issue":"5","key":"1437_CR28","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.annemergmed.2010.11.030","volume":"57","author":"SM Green","year":"2011","unstructured":"Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Ann Emerg Med. 2011;57(5):449\u201361. https:\/\/doi.org\/10.1016\/j.annemergmed.2010.11.030.","journal-title":"Ann Emerg Med"},{"issue":"1","key":"1437_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-025-01360-9","volume":"29","author":"AD Kaye","year":"2025","unstructured":"Kaye AD, et al. Ketamine infusion for complex regional pain syndrome treatment: a narrative review. Curr Pain Headache Rep. 2025;29(1):26. https:\/\/doi.org\/10.1007\/s11916-025-01360-9.","journal-title":"Curr Pain Headache Rep"},{"key":"1437_CR30","doi-asserted-by":"publisher","DOI":"10.52965\/001c.89640","author":"R Gupta","year":"2023","unstructured":"Gupta R, Bhar S. Maintenance IV ketamine therapy in the fibromyalgia patient: a case report. Health Psychol Res. 2023. https:\/\/doi.org\/10.52965\/001c.89640.","journal-title":"Health Psychol Res"},{"issue":"2","key":"1437_CR31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","volume":"179","author":"M Grabski","year":"2022","unstructured":"Grabski M, et al. Adjunctive ketamine with relapse prevention\u2013based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry. 2022;179(2):152\u201362. https:\/\/doi.org\/10.1176\/appi.ajp.2021.21030277.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1437_CR32","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/acem.14159","volume":"28","author":"N Balzer","year":"2021","unstructured":"Balzer N, McLeod SL, Walsh C, Grewal K. Low-dose ketamine for acute pain control in the emergency department: a systematic review and meta\u2010analysis. Acad Emerg Med. 2021;28(4):444\u201354. https:\/\/doi.org\/10.1111\/acem.14159.","journal-title":"Acad Emerg Med"},{"key":"1437_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsat.2017.03.006","volume":"77","author":"Y-I Hser","year":"2017","unstructured":"Hser Y-I, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. Chronic pain among patients with opioid use disorder: results from electronic health records data. J Subst Abuse Treat. 2017;77:26\u201330. https:\/\/doi.org\/10.1016\/j.jsat.2017.03.006.","journal-title":"J Subst Abuse Treat"},{"key":"1437_CR34","unstructured":"Rosenbaum SB, Gupta V, Patel P, Palacios JL. Ketamine, in StatPearls, treasure island (FL). StatPearls Publishing. 2025. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470357\/. Accessed 16 June 2025. [Online]."},{"issue":"2","key":"1437_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1151\/ascp08424","volume":"4","author":"SR Savage","year":"2008","unstructured":"Savage SR, Kirsh KL, Passik SD. Challenges in using opioids to treat pain in persons with substance use disorders. Addict Sci Clin Pract. 2008;4(2):4\u201325. https:\/\/doi.org\/10.1151\/ascp08424.","journal-title":"Addict Sci Clin Pract"},{"key":"1437_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2023-105035","author":"A Elyn","year":"2024","unstructured":"Elyn A, Roussin A, Lestrade C, Franchitto N, Jullian B, Cantagrel N. Low-dose ketamine infusion to facilitate opioid tapering in chronic non-cancer pain with opioid-use disorder: a historical cohort study. Reg Anesth Pain Med. 2024. https:\/\/doi.org\/10.1136\/rapm-2023-105035.","journal-title":"Reg Anesth Pain Med"},{"key":"1437_CR37","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","volume":"151","author":"Y Alnefeesi","year":"2022","unstructured":"Alnefeesi Y, et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693\u2013709. https:\/\/doi.org\/10.1016\/j.jpsychires.2022.04.037.","journal-title":"J Psychiatr Res"},{"key":"1437_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.1011103","volume":"16","author":"M Marchi","year":"2022","unstructured":"Marchi M, et al. The effect of ketamine on cognition, anxiety, and social functioning in adults with psychiatric disorders: a systematic review and meta-analysis. Front Neurosci. 2022;16:1011103. https:\/\/doi.org\/10.3389\/fnins.2022.1011103.","journal-title":"Front Neurosci"},{"key":"1437_CR39","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jad.2025.04.119","volume":"382","author":"MCH Cheng","year":"2025","unstructured":"Cheng MCH, et al. The effects of ketamine and esketamine on measures of quality of life in major depressive disorder and treatment-resistant depression: a systematic review. J Affect Disord. 2025;382:438\u201342. https:\/\/doi.org\/10.1016\/j.jad.2025.04.119.","journal-title":"J Affect Disord"},{"issue":"3","key":"1437_CR40","doi-asserted-by":"publisher","DOI":"10.52965\/001c.38247","volume":"10","author":"DJ Anderson","year":"2022","unstructured":"Anderson DJ, et al. Ketamine-induced cystitis: a comprehensive review of the urologic effects of this psychoactive drug. Health Psychol Res. 2022;10(3):3. https:\/\/doi.org\/10.52965\/001c.38247.","journal-title":"Health Psychol Res"},{"key":"1437_CR41","doi-asserted-by":"publisher","first-page":"795231","DOI":"10.3389\/fnana.2022.795231","volume":"16","author":"JFM Strous","year":"2022","unstructured":"Strous JFM, et al. Brain changes associated with long-term ketamine abuse, a systematic review. Front Neuroanat. 2022;16:795231. https:\/\/doi.org\/10.3389\/fnana.2022.795231.","journal-title":"Front Neuroanat"},{"issue":"1","key":"1437_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-025-01408-w","volume":"29","author":"ED Javaheri","year":"2025","unstructured":"Javaheri ED, et al. Adverse effects associated with high-dose ketamine infusions for refractory pain and psychiatric conditions. Curr Pain Headache Rep. 2025;29(1):93. https:\/\/doi.org\/10.1007\/s11916-025-01408-w.","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"1437_CR43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","volume":"5","author":"B Short","year":"2018","unstructured":"Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5(1):65\u201378. https:\/\/doi.org\/10.1016\/S2215-0366(17)30272-9.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1437_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20190-4","volume":"11","author":"ED Ballard","year":"2020","unstructured":"Ballard ED, Zarate CA. The role of dissociation in ketamine\u2019s antidepressant effects. Nat Commun. 2020;11(1):6431. https:\/\/doi.org\/10.1038\/s41467-020-20190-4.","journal-title":"Nat Commun"},{"key":"1437_CR45","unstructured":"Orhurhu VJ, Vashisht R, Claus LE, Cohen SP. Ketamine toxicity, in StatPearls, treasure island (FL). StatPearls Publishing, 2025. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541087\/. Accessed 16 June 2025. [Online]."},{"issue":"2","key":"1437_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75","author":"EJ Daly","year":"2018","unstructured":"Daly EJ, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatr. 2018;75(2):139\u201348. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.3739.","journal-title":"JAMA Psychiatr"},{"issue":"3","key":"1437_CR47","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18r12475","volume":"80","author":"JD Rosenblat","year":"2019","unstructured":"Rosenblat JD, Carvalho AF, Li M, Lee Y, Subramanieapillai M, McIntyre RS. Oral ketamine for depression: a systematic review. J Clin Psychiatry. 2019;80(3):18r12475. https:\/\/doi.org\/10.4088\/JCP.18r12475.","journal-title":"J Clin Psychiatry"},{"key":"1437_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1141988","volume":"14","author":"PE Wolfson","year":"2023","unstructured":"Wolfson PE, Andries J, Ahlers D, Whippo M. Ketamine-assisted psychotherapy in adolescents with multiple psychiatric diagnoses. Front Psychiatry. 2023;14:1141988. https:\/\/doi.org\/10.3389\/fpsyt.2023.1141988.","journal-title":"Front Psychiatry"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-025-01437-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-025-01437-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-025-01437-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T12:39:39Z","timestamp":1765802379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-025-01437-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1437"],"URL":"https:\/\/doi.org\/10.1007\/s11916-025-01437-5","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previous studies and contains no new studies with human participants or animals performed by any authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Guidelines"}},{"value":"ADK is the Editor in Chief for CPHRs.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9"}}